NCT06267729
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Recruiting · Phase 1, Phase 2 · AstraZeneca · registry updated 2026-02-23
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Inclusion
- Participant must be 18 years or older at the time of signing the informed consent form.
- Type of Participant and Disease Characteristics
- Participants with:
- A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate without known neuroendocrine differentiation or small cell features.
- Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing luteinising hormone-releasing hormone analogue. Participants receiving medical castration therapy with gonadotropin releasing hormone analogues should continue this treatment during the study.
- Measurable PSA \>/=1 ng/mL AND
Exclusion
- Participants with weight less than 39 kg
- History of another primary malignancy except for malignancy treated with curative intent with no known active disease (≥ 2 years) before the first dose of study intervention and of low potential risk for recurrence. Such exceptions include non-melanoma cancer of the skin that has undergone curative therapy or adequately treated carcinoma in situ without evidence of disease.
- Participants with known brain metastases.
- Prior solid organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion:
- Participants with vitiligo or autoimmune alopecia.